Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma

Richard L. Wahl, Christine A. Henry, Stephen P. Ethier

Research output: Contribution to journalArticle


The positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) accumulates into many cancers after intravenous injection, but the effect of serum glucose levels on FDG uptake in the tumor has not been extensively studied. In vitro, elevated media glucose levels markedly diminished FDG and FDG 6-phosphate uptake and retention in human adenocarcinoma cells, while insulin had no effect. Mammary cancers were established subcutaneously in 12 rats. Six control rats with mammary tumors were fasted overnight. Hyperglycemia was established in six rats by means of continuous glucose infusion (glucose clamp). All animals were then intravenously administered 50 μCi of FDG. Serum glucose levels were 87 mg/dL (4.83 mmol/L) in the control animals and more than 900 mg/dL (49.9 mmol/L) in the hyperglycemic animals. One hour after injection of FDG, mean F-18 uptake in the tumor, brain, small bowel, and ovaries was 2.7-9.7 times lower in the hyperglycemic animals (P <.02). Mean F-18 activity in the kidneys tended to be somewhat higher in the hyperglycemic animals. FDG uptake in other tissues was comparable between the control and hyperglycemic groups. These data suggest that high serum glucose levels may substantially impair visceral tumor imaging with FDG positron emission tomography.

Original languageEnglish (US)
Pages (from-to)643-647
Number of pages5
Issue number3
Publication statusPublished - Jun 1992
Externally publishedYes



  • Breast neoplasms, diagnosis, 00.32, 00.33
  • Breast neoplasms, radionuclide studies
  • Emission CT, 00.1299
  • Glucose
  • Radionuclide imaging, in diagnosis of neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this